Koschmieder: Current standard and novel targets for myelofibrosis

Talha Badar shared on X:        .

Koschmieder: novel combination trials

Koschmieder: current standard and novel targets for myelofibrosis in 2024!”

Source: Talha Badar/X

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.